BIIB

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% over the past year as analysts try to keep up with the stock.

B of A Securities keeps Biogen neutral and lifts its price target to $244 from $219. The move reflects a steady outlook for the company.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio, Intellia, Biogen and Viking Therapeutics are all pushing late‑stage drug programs. Upcoming regulatory decisions and trial results will shape their future.

Biogen is rated Hold ahead of its Q3 2026 earnings, with cautious optimism tied to pipeline catalysts. Investors are watching for any signs of disappointment.

TD Cowen upgrades Biogen to a Buy and raises its target to $250 from $225. The rating signals confidence in the company’s prospects.

Wells Fargo keeps Biogen overweight and bumps its target to $310 from $250. The upgrade suggests a positive view of the company’s trajectory.